New federal board gets binding veto over risky life sciences research funding

What it does

This bill creates a new independent federal agency called the Life Sciences Research Security Board to review and approve all federal funding for high-risk life sciences research before money is awarded. The Board—composed of 9 members including scientists, national security experts, and a biosafety expert—has binding authority to block, approve, or impose safety conditions on research involving dangerous pathogens or gain-of-function experiments. Researchers and funding agencies must attest to whether proposed work is high-risk, and the Board has 120 days to decide whether funding can proceed.

Why we flagged it

The bill's core function is to establish an independent expert board with binding authority over federal funding for high-risk life sciences research, particularly gain-of-function and dual-use research involving dangerous pathogens. This is a regulatory/oversight mechanism, not a subsidy, tax provision, or commemorative act.

What the text implies

• The Board's definition of 'high-risk life sciences research' is self-expanding: the Board can unilaterally add new categories by majority vote and Federal Register publication, with no congressional override mechanism, potentially capturing research far beyond the stated pathogen list.
• The 120-day review clock does not stop for Board requests for additional information, creating pressure on agencies to submit incomplete applications or face indefinite delays—a procedural advantage to the Board's authority.
• Researchers and institutions face criminal perjury liability for attestations about whether their work is high-risk, but the Board's own definitions are fluid and subject to retroactive application to ongoing research, creating asymmetric legal risk.
• The bill requires agencies to suspend ongoing research if circumstances change, but provides no compensation mechanism for researchers or institutions whose federally funded work is halted mid-project by Board determination.
• Board members who have participated in high-risk research face mandatory conflict-of-interest review and potential removal, but the bill does not prohibit Board members from having financial interests in companies that benefit from research restrictions or from consulting for agencies seeking Board approval.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates a genuine public-safety mechanism: independent expert review of federally funded research that could produce pandemic pathogens or bioweapons, with binding enforcement and transparency requirements. However, the Board's broad discretion to define what counts as high-risk research, combined with vague risk-benefit balancing language and no explicit public participation or appeal process, creates capture risk and potential for research chilling effects without clear offsetting pub

Named in the bill

Life Sciences Research Security Board, Executive Director of the Board, Department of Defense, Department of Homeland Security, National Institute of Allergy and Infectious Diseases, Office of the Director of National Intelligence, Department of Energy, Committee on Homeland Security and Governmental Affairs (Senate), Committee on Energy and Commerce (House), Director of the Office of Government Ethics, Comptroller General, Select agents and toxins (CDC, USDA, APHIS regulated)

Where it stands

1 cosponsor: 1 Democrats.

• Mar 5, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 5, 2025 — Referred to Senate Committee on Homeland Security and Governmental Affairs · Congress.gov: “Read twice and referred to the Committee on Homeland Security and Governmental Affairs”
• Jul 30, 2025 — Reported out of committee · Congress.gov: “Committee on Homeland Security and Governmental Affairs. Ordered to be reported without amendment favorably”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 12 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $3,060,259 in lobbying spend. A filing names 17 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Rand Paul, the sponsor, reported $94,645 in PAC receipts in the 2026 cycle.

• Association of American Medical Colleges — $1,529,833 on 2 filings
• American Fed of Government Employees AFL-CIO — $840,426 on 2 filings
• University of Michigan — $300,000 on 2 filings
• Johns Hopkins University — $120,000 on 2 filings
• American Society for Microbiology — $100,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.